Cargando…

Cost-effectiveness analysis of ribociclib plus letrozole versus palbociclib plus letrozole in the United Kingdom

OBJECTIVE: To evaluate the cost-effectiveness of ribociclib plus letrozole versus palbociclib plus letrozole in post-menopausal women with hormone receptor positive (HR+) and human epidermal growth receptor 2 negative (HER2−) advanced breast cancer from a UK payer perspective. METHODS: A cohort-base...

Descripción completa

Detalles Bibliográficos
Autores principales:	Suri, Gaurav, Chandiwana, David, Lee, Adam, Mistry, Rohit
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Columbia Data Analytics, LLC 2019
Materias:	General Indications
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7299496/ https://www.ncbi.nlm.nih.gov/pubmed/32685577 http://dx.doi.org/10.36469/9725

Ejemplares similares

Cost-Effectiveness of Ribociclib plus Letrozole Versus Palbociclib plus Letrozole and Letrozole Monotherapy in the First-Line Treatment of Postmenopausal Women with HR+/HER2- Advanced or Metastatic Breast Cancer: A U.S. Payer Perspective
por: Mistry, Rohit, et al.
Publicado: (2018)

Matching-Adjusted Indirect Comparison of Ribociclib Plus Fulvestrant versus Palbociclib Plus Letrozole as First-Line Treatment of HR+/HER2− Advanced Breast Cancer
por: Fasching, Peter A, et al.
Publicado: (2021)

Cost-effectiveness of ribociclib plus letrozole versus palbociclib plus letrozole or letrozole as monotherapy in first-line treatment of postmenopausal women with HR+/HER2− locally advanced or metastatic breast cancer: a Brazilian private payer perspective
por: Buehler, Anna Maria, et al.
Publicado: (2021)

Cost-utility analysis of Palbociclib + letrozole and ribociclib + letrozole versus Letrozole monotherapy in the first-line treatment of metastatic breast cancer in Iran using partitioned survival model
por: Darvishi, Ali, et al.
Publicado: (2023)

Real-world comparative effectiveness of palbociclib plus letrozole versus letrozole in older patients with metastatic breast cancer
por: Rugo, Hope S., et al.
Publicado: (2023)

Real-World Tumor Response of Palbociclib Plus Letrozole Versus Letrozole for Metastatic Breast Cancer in US Clinical Practice
por: Brufsky, Adam, et al.
Publicado: (2021)

Ribociclib plus letrozole versus letrozole alone in patients with de novo HR+, HER2− advanced breast cancer in the randomized MONALEESA-2 trial
por: O’Shaughnessy, Joyce, et al.
Publicado: (2017)

Palbociclib Plus Letrozole for the Treatment of Metastatic Breast Cancer: An Illustrative Case Scenario
por: Orbaugh,1, Kristi, et al.
Publicado: (2016)

Real-World Effectiveness of Palbociclib Plus Letrozole vs Letrozole Alone for Metastatic Breast Cancer With Lung or Liver Metastases: Flatiron Database Analysis
por: Brufsky, Adam, et al.
Publicado: (2022)

Comparative effectiveness of first-line palbociclib plus letrozole versus letrozole alone for HR+/HER2− metastatic breast cancer in US real-world clinical practice
por: DeMichele, Angela, et al.
Publicado: (2021)

Updated results from MONALEESA-2, a phase III trial of first-line ribociclib plus letrozole versus placebo plus letrozole in hormone receptor-positive, HER2-negative advanced breast cancer
por: Hortobagyi, G N, et al.
Publicado: (2019)

Biomarkers of Response and Resistance to Palbociclib Plus Letrozole in Patients With ER(+)/HER2(−) Breast Cancer
por: Dowsett, Mitch, et al.
Publicado: (2022)

Simultaneous quantification of palbociclib, ribociclib and letrozole in human plasma by a new LC-MS/MS method for clinical application
por: Posocco, Bianca, et al.
Publicado: (2020)

Comparative efficacy & safety of buparlisib plus fulvestrant, fulvestrant plus dalpiciclib, and ribociclib plus letrozole for postmenopausal, hormone receptor-positive, and HER2-negative breast cancer
por: Liu, Qi, et al.
Publicado: (2023)

Expanded Access Study of Palbociclib Plus Letrozole for Postmenopausal Women with HR+/HER2− Advanced Breast Cancer in Latin America for Whom Letrozole Therapy is Deemed Appropriate
por: Fein, Luis, et al.
Publicado: (2023)

Phase II randomized trial of neoadjuvant metformin plus letrozole versus placebo plus letrozole for estrogen receptor positive postmenopausal breast cancer (METEOR)
por: Kim, Jisun, et al.
Publicado: (2014)

AMEERA-5: a randomized, double-blind phase 3 study of amcenestrant plus palbociclib versus letrozole plus palbociclib for previously untreated ER+/HER2– advanced breast cancer
por: Bardia, Aditya, et al.
Publicado: (2022)

Correction: Expanded Access Study of Palbociclib Plus Letrozole for Postmenopausal Women with HR+/HER2− Advanced Breast Cancer in Latin America for Whom Letrozole Therapy is Deemed Appropriate
por: Fein, Luis, et al.
Publicado: (2023)

Impact of palbociclib plus letrozole on patient-reported health-related quality of life: results from the PALOMA-2 trial
por: Rugo, H S, et al.
Publicado: (2018)

Acute Lymphoblastic Leukemia in a Patient Treated with Letrozole and Palbociclib
por: Park, Jin Hyun, et al.
Publicado: (2019)

Comparison of ovulation induction with letrozole plus dexamethasone and letrozole alone in infertile women with polycystic ovarian disease: An RCT
por: Farzaneh, Farahnaz, et al.
Publicado: (2020)

Comprehensive Genomic Profiling of Cell-Free Circulating Tumor DNA Detects Response to Ribociclib Plus Letrozole in a Patient with Metastatic Breast Cancer
por: Silveira, Catarina, et al.
Publicado: (2022)

A phase II study of palbociclib plus letrozole plus trastuzumab as neoadjuvant treatment for clinical stages II and III ER+ HER2+ breast cancer (PALTAN)
por: Ademuyiwa, Foluso O., et al.
Publicado: (2023)

Ribociclib with letrozole vs letrozole alone in elderly patients with hormone receptor-positive, HER2-negative breast cancer in the randomized MONALEESA-2 trial
por: Sonke, Gabe S., et al.
Publicado: (2017)

A Cost-benefit Analysis of Using Polyethylene Glycol Hydrogel Sealant versus Fibrin Glue as a Dural Sealant for Posterior Fossa Surgery in the United States
por: Carter, Marissa J.
Publicado: (2017)

Durable response to palbociclib and letrozole in ovarian cancer with CDKN2A loss
por: Frisone, Daniele, et al.
Publicado: (2019)

Estimating the Burden of Cost in Chronic Graft-versus-Host Disease: A Human Capital Approach
por: Jones, Chris A., et al.
Publicado: (2016)

Economic Evaluation for Palbociclib Plus Fulvestrant vs Ribociclib Plus Fulvestrant and Abemaciclib Plus Fulvestrant in Endocrine-Resistant Advanced or Metastatic Breast Cancer in Italy
por: Colombo, Giorgio Lorenzo, et al.
Publicado: (2023)

Palbociclib plus letrozole as treatment for postmenopausal women with hormone receptor–positive/human epidermal growth factor receptor 2–negative advanced breast cancer for whom letrozole therapy is deemed appropriate: An expanded access study in Australia and India
por: Loi, Sherene, et al.
Publicado: (2021)

L-BLP25 vaccine plus letrozole for breast cancer: Is translation possible?
por: DeGregorio, Michael, et al.
Publicado: (2012)

Phase II trial of ribociclib and letrozole in patients with relapsed oestrogen receptor-positive ovarian or endometrial cancers
por: Colon-Otero, Gerardo, et al.
Publicado: (2020)

Palbociclib Plus Letrozole as First-Line Therapy in Postmenopausal Asian Women With Metastatic Breast Cancer: Results From the Phase III, Randomized PALOMA-2 Study
por: Im, Seock-Ah, et al.
Publicado: (2019)

Combined letrozole and clomiphene versus letrozole and clomiphene alone in infertile patients with polycystic ovary syndrome
por: Hajishafiha, Masomeh, et al.
Publicado: (2013)

Efficacy, Safety, and Prognosis of Sequential Therapy with Tamoxifen and Letrozole versus Letrozole Monotherapy for Breast Carcinoma
por: Lu, Xinli, et al.
Publicado: (2022)

Development and Validation of a Novel LC-MS/MS Method for the Simultaneous Determination of Abemaciclib, Palbociclib, Ribociclib, Anastrozole, Letrozole, and Fulvestrant in Plasma Samples: A Prerequisite for Personalized Breast Cancer Treatment
por: Turković, Lu, et al.
Publicado: (2022)

Matching-adjusted indirect treatment comparison of ribociclib and palbociclib in HR+, HER2− advanced breast cancer
por: Tremblay, Gabriel, et al.
Publicado: (2018)

Combined letrozole and clomiphene versus letrozole and clomiphene alone in infertile patients with polycystic ovary syndrome [Erratum]
Publicado: (2017)

Retracted: Efficacy, Safety, and Prognosis of Sequential Therapy with Tamoxifen and Letrozole versus Letrozole Monotherapy for Breast Carcinoma
por: Methods in Medicine, Computational and Mathematical
Publicado: (2023)

A comparison of letrozole and anastrozole followed by letrozole in breast cancer patients
por: Aphinives, Potchavit, et al.
Publicado: (2015)

Robotic-Arm Assisted Technology’s Impact on Knee Arthroplasty and Associated Healthcare Costs
por: Kolessar, David J., et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_dso89th6vum7lemdk98242tdtt